A number of other equities research analysts also recently weighed in on AZN. Liberum Capital reaffirmed a hold rating on shares of AstraZeneca in a research report on Friday. UBS Group reaffirmed a neutral rating and set a GBX 5,900 ($77.09) price objective on shares of AstraZeneca in a research report on Monday, November 19th. JPMorgan Chase & Co. reaffirmed an overweight rating on shares of AstraZeneca in a research report on Monday, November 19th. Shore Capital reaffirmed a hold rating on shares of AstraZeneca in a research report on Tuesday, October 30th. Finally, BNP Paribas set a GBX 6,500 ($84.93) price objective on shares of AstraZeneca and gave the company a buy rating in a research report on Tuesday, September 11th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company. AstraZeneca currently has an average rating of Hold and an average target price of GBX 5,927.44 ($77.45).
Shares of LON:AZN opened at GBX 5,927 ($77.45) on Friday. AstraZeneca has a fifty-two week low of GBX 4,260 ($55.66) and a fifty-two week high of GBX 5,520 ($72.13).
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: Understanding Analyst Ratings
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.